Who are Ninlaro's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kyprolis, Velcade, Drug: Carfilzomib + Dexamethasone, PAD combination, VRD for first-cycle induction therapy, Drug: Carfilzomib + Lenalidomide + Dexamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ixazomib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ninlaro — Competitive Intelligence Brief

Ninlaro (IXAZOMIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome Inhibitor. Area: Oncology.

marketed Proteasome Inhibitor Proteasome subunit beta type-5 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ninlaro (IXAZOMIB) — Takeda. Ninlaro blocks the action of proteasomes, which are cellular complexes that break down and recycle proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ninlaro TARGET	IXAZOMIB	Takeda	marketed	Proteasome Inhibitor	Proteasome subunit beta type-5	2015-01-01
Kyprolis	carfilzomib	Amgen	marketed	Proteasome Inhibitor [EPC]	Proteasome subunit beta type-5	2012-01-01
Velcade	bortezomib	Shilpa	marketed	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
Drug: Carfilzomib + Dexamethasone	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-11-03 — Velcade · 8962572 · Formulation · US
2042-09-23 — Velcade · 11752164 · Method of Use · US
2042-09-23 — Velcade · 11679119 · Method of Use · US
2042-09-23 — Velcade · 12005069 · Formulation · US

Sponsor landscape (Proteasome Inhibitor class)

Millennium Pharms · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ninlaro — Competitive Intelligence Brief. https://druglandscape.com/ci/ixazomib. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab